Multiple Myeloma
By Chase Doyle
San Diego, CA—The results of a phase 2 clinical trial presented at ASH 2018 suggest that early therapeutic intervention is beneficial in patients with high-risk smoldering multiple myeloma.
Read ArticleBy Phoebe Starr
San Diego, CA—A dizzying array of new chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) designed specifically for the treatment of multiple myeloma was presented at ASH 2018. BCMA-targeted CAR T-cell therapies are designed to improve T-cell persistence, depth of response, and tolerability. Response rates reported at ASH 2018 range from 70% to 100%, depending on the patient population and the use of previous regimens.
Read ArticleBy Wayne Kuznar
San Diego, CA—Interim analysis of an international phase 3 clinical trial supports the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone as the new standard of care in patients with newly diagnosed multiple myeloma who are transplant-ineligible.
Read ArticleOn February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Darzalex is the first and only CD38-directed antibody to receive regulatory approval for the treatment of patients with MM and is the first to be approved for the split-dosing regimen. This new regimen gives patients and healthcare providers the option to split the first dose of Darzalex over the course of 2 consecutive days, which has the benefit of shortening the duration of the first infusion.
Read ArticleSan Diego, CA—In patients with multiple myeloma (MM), the use of drug therapy as maintenance has been shown to prolong the length of time the disease is controlled. Specifically, use of maintenance therapy may affect overall survival, particularly when it is used after an autologous stem-cell transplant (ASCT).
Read ArticleOnce-weekly carfilzomib (Kyprolis) therapy at a higher dose significantly improved progression-free survival (PFS) and reduced the risk of disease progression or death compared with twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma. The overall safety profile for both regimens in the randomized phase 3 ARROW clinical trial were similar, said co-lead investigator María-Victoria Mateos, MD, PhD, Director, Myeloma Unit, University Hospital Salamanca-IBSAL, Spain, at the 2018 European Hematology Association Congress.
Read ArticleBy Wayne Kuznar
Orlando, FL—The 2018 National Comprehensive Cancer Network (NCCN) updated guideline on the management of multiple myeloma assigns preferred status to certain treatment regimens, and designates others as recommended or useful in certain circumstances.
Read Article